Association between age and disease specific mortality in medullary thyroid cancer

2020 ◽  
Author(s):  
Zeyad T. Sahli ◽  
Joseph K. Canner ◽  
Martha A. Zeiger ◽  
Aarti Mathur
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Disease Specific

scholarly journals Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study

2017 ◽  
Vol 102 (4) ◽  
pp. 1254-1260 ◽  
Author(s):  
Palak Choksi ◽  
Maria Papaleontiou ◽  
Cui Guo ◽  
Francis Worden ◽  
Mousumi Banerjee ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Prognostic Indicator ◽  
Medullary Thyroid ◽  
Specific Mortality ◽  
Skeletal Complications ◽  
Disease Specific Mortality ◽  
Poor Prognostic Indicator ◽  
The Impact ◽  
Disease Specific

Abstract Context: Although bone is a common site for tumor metastases, the burden of bone events [bone metastases and skeletal-related events (SREs)] in patients with thyroid cancer is not well known. Objective: To measure the prevalence of bone events and their impact on mortality in patients with thyroid cancer. Patients, Design, and Setting: We identified patients diagnosed with thyroid cancer between 1991 and 2011 from the linked Surveillance Epidemiology and End Results–Medicare dataset. Multivariable logistic regression was used to identify the risk factors for bone metastases and SREs. We used Cox proportional hazards regressions to assess the impact of these events on mortality, after adjusting for patient and tumor characteristics. Results: Of the 30,063 patients with thyroid cancer, 1173 (3.9%) developed bone metastases and 1661 patients (5.5%) developed an SRE. Compared with papillary thyroid cancer, the likelihood of developing bone metastases or an SRE was higher in follicular thyroid cancer [odds ratio (OR), 2.25; 95% confidence interval (CI), 1.85 to 2.74 and OR, 1.40; 95% CI, 1.15 to 1.68, respectively] and medullary thyroid cancer (OR, 2.16; 95% CI, 1.60 to 2.86 and OR, 1.62; 95% CI, 1.23 to 2.11, respectively). The occurrence of a bone event was associated with greater risk of overall and disease-specific mortality [hazard ratio (HR), 2.14; 95% CI, 1.94 to 2.36 and HR, 1.59; 95% CI, 1.48 to 1.71, respectively]. Bone events were a poor prognostic indicator even when compared with patients with other distant metastases (P < 0.001 and P < 0.001 for overall and disease-specific mortality, respectively). Conclusions: Bone events in patients with thyroid cancer are a poor prognostic indicator. Patients with follicular and medullary thyroid cancers are at especially high risk for skeletal complications.

scholarly journals Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer

2014 ◽  
Vol 22 (8) ◽  
pp. 2700-2706 ◽  
Author(s):  
Allen S. Ho ◽  
Lu Wang ◽  
Frank L. Palmer ◽  
Changhong Yu ◽  
Arnbjorn Toset ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Specific Mortality ◽  
Cancer Specific Mortality

scholarly journals Therapeutic Outcomes of Recurrent Well-Differentiated Thyroid Carcinomas

2019 ◽  
Vol 104 (7-8) ◽  
pp. 304-313
Author(s):  
Chih-Yiu Tsai ◽  
Shu-Fu Lin ◽  
Szu-Tah Chen ◽  
Chuen Hsueh ◽  
Yann Sheng Lin ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Recurrent Disease ◽  
Differentiated Thyroid Carcinoma ◽  
Thyroid Carcinomas ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Well Differentiated ◽  
Disease Specific

Objective The aim of this study was to evaluate outcomes of the recurrent and non-recurrent groups including disease-specific mortality of patients with well-differentiated thyroid carcinoma after multimodality treatment. In addition, prognostic factors for disease-specific mortality were analyzed. Summary of Background Data Among 2,844, there were 166 patients with recurrent disease. Recurrent disease was defined as the presence of papillary or follicular thyroid cancer 6 months after the initial thyroidectomy, including locoregional or distant metastasis, diagnosed using diagnostic or therapeutic 131I scans or other imaging techniques. Methods The study was a retrospective analysis of prospectively collected data for a long-term follow-up result of well-differentiated thyroid carcinoma patients. Results The mean age of 166 patients was 45.8 ± 1.2 years, 116 (69.9%) were women, 111 (66.9%) had locoregional neck recurrence, and 55 (33.1%) had metastatic recurrence in distant organs. We found that when recurrences were observed, more than half were detected within the first 5 years following the initial therapy. The longest period of time before relapse was 29.8 years. After a mean follow-up period of 12.7 ± 0.5 years, 37 (22.3%) patients experienced disease-specific mortality. Multivariable analysis revealed that older age, male sex, and development of a second primary malignancy were associated with disease-specific mortality. Higher post-operative levels of thyroglobulin predicted a shorter time to relapse. Conclusions These data indicate that among the recurrent cases over 50% of recurrent well-differentiated thyroid carcinomas were diagnosed within 5 years after initial thyroidectomy. Additionally, more than 20% of the patients died of thyroid cancer.

scholarly journals Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up

2019 ◽  
Vol 104 (9) ◽  
pp. 4087-4100 ◽  
Author(s):  
R Michael Tuttle ◽  
Ali S Alzahrani
Keyword(s):  
Thyroid Cancer ◽  
Risk Stratification ◽  
Differentiated Thyroid Cancer ◽  
Initial Therapy ◽  
Cancer Management ◽  
Individualized Care ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Disease Specific

Abstract Context Modern management of differentiated thyroid cancer requires individualized care plans that tailor the intensity of therapy and follow-up to the estimated risks of recurrence and disease-specific mortality. Design This summary is based on the authors’ knowledge and extensive clinical experience, supplemented by review of published review articles, thyroid cancer management guidelines, published staging systems, and original articles identified through a PubMed search, which included terms such as risk stratification, staging, clinical outcomes, and differentiated thyroid cancer. Main Outcome Measures In the past, risk stratification in differentiated thyroid cancer usually referred to a static estimate of disease-specific mortality that was based on a small set of clinicopathological features available within a few weeks of completing initial therapy (thyroidectomy, with or without radioactive iodine). Today, risk stratification is a dynamic, active process used to predict the appropriateness for minimalistic initial therapy, disease-specific mortality, risk of recurrence, and the most likely response to initial therapy. Rather than being a static prediction available only after initial therapy, modern risk stratification is a dynamic, iterative process that begins as soon as a suspicious nodule is detected and continues through final follow-up. Conclusions Dynamic risk assessment should be used to guide all aspects of thyroid cancer management, beginning before a definitive diagnosis is made and continuing through the final follow-up visit.

Risk factors associated with disease-specific mortality in papillary thyroid cancer patients with distant metastases

Endocrine ◽  
2021 ◽  
Author(s):  
Kamilla Schmitz Nunes ◽  
Leandro Luongo Matos ◽  
Beatriz Godoi Cavalheiro ◽  
Felipe Ferraz Magnabosco ◽  
Marcos Roberto Tavares ◽  
...  
Keyword(s):  
Risk Factors ◽  
Thyroid Cancer ◽  
Cancer Patients ◽  
Papillary Thyroid Cancer ◽  
Distant Metastases ◽  
Papillary Thyroid ◽  
Factors Associated ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Disease Specific

scholarly journals Thyroid Cancer in Saudi Arabia: A Histopathological and Outcome Study

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Ali S. Alzahrani ◽  
Haneen Alomar ◽  
Nada Alzahrani
Keyword(s):  
Saudi Arabia ◽  
Thyroid Cancer ◽  
Middle Eastern ◽  
Western World ◽  
Follicular Variant ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Radioactive Iodine Ablation ◽  
Disease Specific

Most data on differentiated thyroid cancer (DTC) came from the Western world. We describe its salient characteristics and outcome from a Middle Eastern country.Patients and Methods. We studied all cases of TC seen during a 2-year period (2004-2005) seen at our institution.Results. A total of 600 consecutive cases of DTC with a median age at diagnosis of 39 years (5–85) and the female : male ratio of 459 : 141 (76.5% : 23.5%). The cases included classical papillary thyroid cancer (PTC) in 77%, follicular variant PTC in 13.3%, follicular thyroid cancer in 3.2%, and other rare subtypes 6.5%. Total or near-total thyroidectomy was performed in 93%, central and/or lateral neck dissection in 64.5% of cases, and radioactive iodine ablation in 82% of cases. Additional therapies were administered to 154 patients (25.7%). At a median follow-up period of 7.63 years (0.22–13.1), 318 patients (53.3%) were in excellent response, 147 (24.5%) having an indeterminate response, 55 (9.2%) biochemically incomplete, 33 (5.5%) structurally incomplete, and 27 (4.5%) unclassifiable. Twenty cases died secondary to DTC (disease-specific mortality 3.3%).Conclusions. In Saudi Arabia, DTC is common and occurs at young age and predominantly in females. Although remission is common, persistent disease is also common but disease-specific mortality is low.

Sign in / Sign up

Export Citation Format

Share Document